BR112017010101A2 - uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central - Google Patents

uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central

Info

Publication number
BR112017010101A2
BR112017010101A2 BR112017010101A BR112017010101A BR112017010101A2 BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2 BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A BR112017010101 A BR 112017010101A BR 112017010101 A2 BR112017010101 A2 BR 112017010101A2
Authority
BR
Brazil
Prior art keywords
central nervous
checkpoint inhibitors
neoplasms
nervous system
immune system
Prior art date
Application number
BR112017010101A
Other languages
English (en)
Portuguese (pt)
Inventor
CHENG Shinta
Coric Vladimir
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112017010101A2 publication Critical patent/BR112017010101A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR112017010101A 2014-12-16 2015-12-16 uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central BR112017010101A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US201562261130P 2015-11-30 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Publications (1)

Publication Number Publication Date
BR112017010101A2 true BR112017010101A2 (pt) 2018-01-02

Family

ID=56127849

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017010101A BR112017010101A2 (pt) 2014-12-16 2015-12-16 uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central

Country Status (9)

Country Link
US (3) US20180133313A1 (enExample)
EP (1) EP3233123A4 (enExample)
JP (2) JP2018500332A (enExample)
CN (1) CN106999590A (enExample)
BR (1) BR112017010101A2 (enExample)
CA (1) CA2969338A1 (enExample)
MX (1) MX2017007390A (enExample)
RU (1) RU2726996C1 (enExample)
WO (1) WO2016100561A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
JP2018515474A (ja) * 2015-04-28 2018-06-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
FI3334763T3 (fi) 2015-08-11 2024-10-30 Wuxi Biologics Ireland Ltd Uusia pd-l1-vasta-aineita
HK1257840A1 (zh) 2015-09-01 2019-11-01 Agenus Inc. 抗-pd-1抗体及其使用方法
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
EP3497129A1 (en) * 2016-08-08 2019-06-19 H. Hoffnabb-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
WO2018106729A1 (en) * 2016-12-05 2018-06-14 G1 Therapeutics, Inc. Preservation of immune response during chemotherapy regimens
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
EP3551225A1 (en) 2016-12-07 2019-10-16 Agenus Inc. Antibodies and methods of use thereof
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
US10617667B2 (en) * 2017-11-01 2020-04-14 Ono Pharmaceutical Co., Ltd. Method for treating brain tumors
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
CN112203688A (zh) * 2018-05-31 2021-01-08 小野药品工业株式会社 用于确定免疫检查点抑制剂的有效性的生物标志物
EP3941467A4 (en) * 2019-03-19 2022-12-21 ChemoCentryx, Inc. MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
EP4028052A1 (en) * 2019-09-10 2022-07-20 Novocure GmbH A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells
WO2021127254A1 (en) * 2019-12-19 2021-06-24 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
WO2021132636A1 (ja) * 2019-12-27 2021-07-01 特定非営利活動法人Ｎｏｒｔｈ Ｅａｓｔ Ｊａｐａｎ Ｓｔｕｄｙ Ｇｒｏｕｐ がん治療方法及び医薬
CN115697374A (zh) * 2020-05-12 2023-02-03 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022032312A1 (en) * 2020-08-07 2022-02-10 Northwestern University Methods of treating malignant glioblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2927240A1 (en) * 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
ES2592216T3 (es) * 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
EP2723381A4 (en) * 2011-06-21 2015-03-18 Univ Johns Hopkins FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS
US9856320B2 (en) * 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Also Published As

Publication number Publication date
US20210000953A1 (en) 2021-01-07
WO2016100561A3 (en) 2016-08-18
WO2016100561A2 (en) 2016-06-23
CA2969338A1 (en) 2016-06-23
CN106999590A (zh) 2017-08-01
EP3233123A4 (en) 2018-05-09
US20180133313A1 (en) 2018-05-17
JP2021181482A (ja) 2021-11-25
JP2018500332A (ja) 2018-01-11
US20240238416A1 (en) 2024-07-18
RU2726996C1 (ru) 2020-07-17
MX2017007390A (es) 2017-11-06
EP3233123A2 (en) 2017-10-25

Similar Documents

Publication Publication Date Title
BR112017010101A2 (pt) uso de inibidores de ponto de verificação do sistema imune em neoplasias do sistema nervoso central
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
MX2017005553A (es) Terapia de combinacion para cancer.
MX2016010080A (es) Combinacion de un antagonista de muerte programada-1 y un inhibidor de indolamina 2,3-dioxigenasa 1 para el tratamiento del cancer.
BR112017017927A2 (pt) receptores quiméricos de antígenos anti-dll3 e métodos de uso
CL2018002012A1 (es) Derivados de maitansinoide, conjugados de los mismos y métodos de uso.
CO2018000244A2 (es) Anticuerpos madurados por afinidad y humanizados para fcrh5
CR20170230A (es) Anticuerpos anti-cd79b y métodos de uso
CL2018000744A1 (es) Anticuerpos anti-tigit (inmunoreceptor de linfocitos t con dominios ig e itim) y metodos de uso.
CO2017010618A2 (es) Anticuerpos contra icos
BR112017011932A8 (pt) Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
BR112016014952A2 (pt) Inibição direcionada de tgfbeta
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CL2016000341A1 (es) Métodos para tratar la miositis por cuerpos de inclusión esporádica
MX388015B (es) Un anticuerpo anti-csf1r y al menos un agente inmuno-estimulador para usarse en el tratamiento de cáncer.
BR112016017256A2 (pt) combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
BR112017009517A2 (pt) receptores de antígeno quimérico anti-cldn e métodos de uso
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016029860A2 (pt) conjugados de anticorpo antirreceptor alfa de folato (fra)-fármaco e métodos de uso dos mesmos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements